Novartis Pharmaceuticals Corp., et al. v. Breckenridge Pharmaceutical, Inc., et al. Civil Action No. 14-1043-RGA (District of Delaware) – Challenging patents on everolimus (Zortress).
Acorda Therapeutics, Inc., et al. v. Accord Healthcare, Inc., et al. Civil Action No.: 1:14-cv-00932-LPS (District of Delaware) – Challenging patents on dalfampridine (Ampyra).
Hospira, Inc. and Orion Corporation v. Intas Pharmaceuticals Ltd. and Accord Healthcare, Inc. USA. Civil Action No.: 1:14-cv-336-JLW (Middle District of North Carolina) – Challenging a method of treatment patent on dexmedetomidine (Precedex).
Sanofi and Sanofi-Aventis U.S. LLC. v. Alembic Pharmaceuticals Limited. Civil Action No.: 14-424 (RGA) (District of Delaware) – Challenging patents on dronedarone hydrochloride (Multaq).
G.D. Searle LLC and Pfizer Asia Pacific Pte. Ltd. v. Watson Laboratories, Inc., et al. Case No. 2:13-cv-121 (Eastern District of Virginia) - Represented Watson against G.D. Searle and Pfizer Asia Pacific against allegations of patent infringement in a Hatch-Waxman action regarding Celebrex®. The district court found the patent invalid
Horizon Pharma AG and Jagotec AG v. Watson Laboratories, Inc., Florida. Case No. 1:13-cv-05124 (District of New Jersey) - Challenging formulation patents on prednisone delayed release (Rayos)
Gilead Sciences, Inc. et al. v. Cipla Limited. Case No. 1:12-CV-06350 (Southern District of New York) - Challenging compound patents on emtricitabine.
Gilead Sciences, Inc. et al. v. Cipla Limited. Case No. 1:12-CV-06351 (Southern District of New York) - Challenging compound patents on tenofovir
Pfizer et al. v. Breckenridge Pharmaceutical, Inc., Alembic Ltd., et al. Case No. 1:12-CV-00810 (District of Delaware) - Challenging compound patents on O-desmethylvenlafaxine succinate (Pristiq)
Ferring B.V. v. Watson Laboratories, Inc., Florida. Case No. 3:11-CV-00481 (District of Nevada) - Challenging formulation claims on tranexamic acid tablets (Lysteda)
Warner Chilcott Company and Warner Chilcott (US), LLC v. Watson Laboratories, Inc., Florida. Case No. 11-5989 (District of New Jersey) - Challenging formulation patents on risedronate sodium (Atelvia)
Represents and advises generic pharmaceutical manufacturers on strategies for obtaining samples of REMS (Risk Evaluation and Mitigation Strategies) designated products.
Reckitt Benckiser, Inc. v. Watson Laboratories, Inc., Florida, Case No. 09-60609 (Southern District of Florida) - Won a seven-day trial defending Watson Laboratories, Inc., against allegations of patent infringement in a Hatch-Waxman action regarding extended release guaifenesin
In re Brimonidine Patent Litigation, Civil Action No. 07-MD-01866 (District of Delaware) - Represented Exela PharmSci., Inc., in a patent infringement action under the Hatch-Waxman Act brought by Allergan regarding brimonidine tartrate
Certain Sucralose, Sweeteners Containing Sucralose, and Related Intermediate Compounds Thereof, Inv. No. 337-TA-604 - Represented six different respondents, including two manufacturers in China, in a case brought by Tate & Lyle alleging infringement of process patents relating to the production of sucralose and certain intermediate compounds. In September 2008, the ALJ issued an initial determination finding no violation by our clients based on non-infringement and other grounds. On April 4, 2009, after a full review of the decision, the commission upheld the ALJ's findings that there was no violation of Section 337, resulting in a complete victory for our clients.
Yu et al (Human Genome Sciences, Inc.) v. Browning et al (Biogen Idec) Browning v. Yu, Interference No. 105,485 - Represented Human Genome Sciences in an interference proceeding relating to LymphoStat-B, a human monoclonal antibody that inhibits the biological activity of B-lymphocyte stimulator (BLyS), before the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences
Enzo Therapeutics, Inc. v. Yeda Research & Dev. Co., (Eastern District of Virginia) 467 F. Supp.2d 579, 477 F. Supp.2d 699 - Represented Yeda Research and Development Co. in a 146 Action involving interferon-β2
DeLucas (Fluidigm Corp.) v. Santarsiero (Takeda San Diego), Interference No. 105,403 - Represented Fluidigm Corp. in an interference where the Board of Patent Appeals and Interferences invalidated more than 400 claims from Takeda San Diego's patents
Represents clients involved in inter partes disputes before the United States Patent and Trademark Office’s Patent Trial and Appeal Board
Regularly represents generic pharmaceutical clients in the review, identification and analysis of competitor's patents for target products
Frequently prepares opinions and countless product clearance evaluations as well as representing investors in patent diligence matters for chemical, medical device, life science and pharmaceutical companies